Press Releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2006 Press Releases

Listed below are all of the QLT press releases available for the year you have selected.

December 22	QLT Announces Divestment of QLT USA, Inc.'s Generic Dermatology and Manufacturing Business	PDF version
December 19	QLT Signs Research Collaboration and Option Agreement with Wilmer Eye Institute at Johns Hopkins University for Research and Development of Potential Treatments for Dry AMD	PDF version
December 1	Eligard® Six-Month Formulation Approved in Germany	PDF version
November 28	Dr. Bruce Carter Joins QLT's Board of Directors	PDF version
November 7	QLT Announces Positive Findings From Phase IV G6PD Deficiency Study for Aczone ™ in Acne	PDF version
November 6	QLT Announces Jury Decision on Trial of Massachusetts Eye and Ear Infirmary Litigation	PDF version
October 26	QLT Announces Q3 Results for 2006, Updates Guidance, and Implements Cost Reductions	PDF version
October 19	QLT Announces Visudyne Sales for the Third Quarter of 2006 and Updates Annual Sales Guidance	PDF version
October 6	QLT Provides Update on Massachusetts Eye and Ear Infirmary Litigation	PDF version
September 14	QLT Announces Final Results of Tender Offer	PDF version
September 11	QLT Announces Preliminary Results of Tender Offer	PDF version
August 3	QLT Announces Commencement of Tender Offer	PDF version
July 27	QLT to Repurchase up to 13 Million Common Shares, This Represents Approximately 15% of Shares Outstanding	PDF version
July 27	QLT Announces Q2 Results for 2006 and Provides Further Guidance	PDF version
July 17	QLT Announces Visudyne® Sales for Second Quarter of 2006	PDF version
June 13	Dr. Ian John Massey Joins QLT's Board of Directors	PDF version
May 25	QLT Strengthens Corporate Development and Legal Functions with the Appointment of Peter J. O'Callaghan as Senior Vice President, Corporate Development and General Counsel	PDF version
May 18	QLT Delays Initiation of Phase IIa Atrigel/Octreotide Program	PDF version
May 8	QLT Announces TSX Approval of Second Year of Two-Year Share Repurchase Program	PDF version
April 27	QLT Announces Q1 Results for 2006 and Provides R&D Guidance	PDF version
April 24	QLT Announces Visudyne® Sales for First Quarter of 2006	PDF version
April 5	QLT Announces that Court of Appeals Grants Stay of Injunction Against Eligard Sales	PDF version
April 5	QLT Announces Co-Development and Licensing Agreement with Retinagenix for early stage ocular synthetic retinoid program	PDF version
March 6	QLT Updates on the U.S. Eligard® Patent Litigation	PDF version
February 27	QLT intends to appeal U.S. Eligard Injunction	PDF version
February 27	QLT's Board of Directors Appoints Robert Butchofsky as CEO	PDF version
February 22	QLT Announces 2005 Results and Visudyne Sales Guidance for 2006	PDF version
February 14	QLT Announces Preliminary Findings from Phase II Clinical Trial of Lemuteporfin-Injectable in BPH	PDF version
January 20	QLT Announces Trial Court Decision in Ongoing Eligard® Patent Litigation and its Intention to Appeal	PDF version
January 19	QLT Announces Visudyne Sales for Fourth Quarter and Fiscal Year 2005	PDF version

Visudyne® is a registered trademark of Novartis AG

Vancouver Web Design by Graphically Speaking